Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Altimmune, Inc. (ALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Altimmune’s common stock, par value $0.0001 per share, is registered on The Nasdaq Global Market under the symbol ALT, and its Exchange Act and Securities Act filings offer detailed insight into its clinical, financial and corporate activities.
For a late clinical-stage company focused on peptide-based therapeutics for liver, metabolic and cardiometabolic diseases, periodic reports and current reports are particularly important. Forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q (when available) describe Altimmune’s business, risk factors, clinical programs and financial condition. Current reports on Form 8-K document material events, including clinical trial results for pemvidutide, Fast Track and Breakthrough Therapy designations, equity distribution agreements for at-the-market offerings, amendments to loan facilities, executive transitions and annual meeting outcomes.
Altimmune’s proxy materials, such as the definitive proxy statement on Form DEF 14A, outline governance matters, board composition, executive compensation and items submitted to stockholders at the annual meeting. These filings help investors understand how the company is overseen and how leadership is incentivized as it advances pemvidutide through Phase 2 and prepares for planned Phase 3 development in MASH.
On Stock Titan, Altimmune filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key terms in agreements such as loan amendments or equity distribution arrangements, and make it easier to locate information on topics like clinical milestones, financing capacity or voting results. Users can also review disclosures related to capital structure, including at-the-market programs and term loan facilities, to see how Altimmune funds its liver and cardiometabolic disease pipeline.
Altimmune, Inc. Chief Business Officer Raymond M. Jordt reported an RSU vesting and related tax withholding transaction. On January 25, 2026, 14,600 Restricted Stock Units were converted into an equal number of Altimmune common shares at an exercise price of $0.
On the same date, 3,855 common shares were surrendered to Altimmune at $5.5 per share to cover taxes due on the RSU vesting. After these transactions, Jordt directly held 53,915 shares of common stock and 29,200 RSUs. The RSUs vest in substantially equal annual installments over four years following January 25, 2024, contingent on continued service.
Altimmune director Vipin K. Garg reported an RSU vesting and related tax share surrender. On January 25, 2026, 42,050 Restricted Stock Units were converted into 42,050 shares of common stock at a stated price of $0 per share. On the same date, 17,984 shares of common stock were surrendered to Altimmune at $5.50 per share to cover taxes due on the RSU vesting. After these transactions, Garg directly holds 379,148 shares of Altimmune common stock and 84,100 RSUs, which vest in substantially equal annual installments over four years starting January 25, 2024.
Altimmune, Inc. Chief Scientific Officer Roberts M. Scot reported routine equity compensation activity. On January 25, 2026, 14,600 Restricted Stock Units were converted into an equal number of Altimmune common shares at a price of $0 per share, reflecting RSU vesting. On the same date, 4,373 common shares were surrendered to the company at $5.50 per share to cover taxes associated with the RSU vesting, rather than being sold on the open market. After these transactions, Scot directly beneficially owned 84,293 shares of common stock and 29,200 RSUs, which continue to vest in substantially equal annual installments over four years following January 25, 2024, conditioned on continued service.
Altimmune, Inc. director Wayne Pisano reported buying additional company stock. On January 8, 2026, he purchased 5,000 shares of Altimmune common stock at a price of $4.082 per share. After this transaction, he directly owns 13,498 shares of Altimmune common stock. This activity was disclosed in a Form 4 insider trading report filed for a single reporting person.
Altimmune, Inc. filed Amendment No. 1 to a Form S-3 shelf registration to register up to $400,000,000 of common stock, preferred stock, debt securities, warrants, and units. The amendment adds Rule 473(a) language for delayed effectiveness. The preliminary prospectus states the company may offer these securities from time to time, separately or in units, with specific terms and any underwriters or agents to be set in a future prospectus supplement.
Altimmune indicates net proceeds from any future sales will be used for general corporate purposes, including research and clinical development, working capital, and capital expenditures. No securities can be sold until a prospectus supplement is delivered after effectiveness. The company’s common stock trades on Nasdaq as “ALT.” As of November 5, 2025, Altimmune had 104,342,385 shares of common stock outstanding.
Altimmune (ALT) Form 4: Chief Financial Officer Gregory Weaver reported equity award activity on 11/11/2025. 18,750 shares of Common Stock were acquired at $0 via the vesting and settlement of Restricted Stock Units (transaction code M). To cover taxes on vesting, 5,672 shares were surrendered at $4.28 (transaction code F). Following these transactions, he directly holds 23,078 shares of Common Stock.
The filing shows 56,250 RSUs remaining after the reported activity. Per the award terms, RSUs vest over four years, with 25% vesting on November 11, 2025 and the remainder in equal annual installments over the next three years, subject to continued service.
Altimmune, Inc. filed a Form S-3 shelf registration to offer from time to time up to $400,000,000 of mixed securities, including common stock, preferred stock, debt securities, warrants and units. Any specific terms and sale methods will be set in a future prospectus supplement.
Sales may occur through underwriters, agents or direct transactions, after effectiveness. Net proceeds, if and when securities are sold, are intended for general corporate purposes, including research and clinical development, working capital and capital expenditures.
Altimmune’s common stock trades on Nasdaq under “ALT”; the shares closed at $3.75 on November 5, 2025. Shares outstanding were 104,342,385 as of November 5, 2025; this is a baseline figure, not the amount being offered.
Recent updates in the company overview include an amended Hercules term loan facility with availability increased to $125.0 million in tranches and a new $200.0 million ATM program with Leerink Partners.
Altimmune, Inc. established a new at-the-market equity offering program, allowing it to sell shares of common stock, from time to time at its sole discretion, for up to $200.0 million through Leerink Partners LLC as sales agent. Sales may be made on Nasdaq or other trading markets under an effective Form S-3 and related prospectus supplement, with a sales agent commission of up to 3.0% of gross proceeds.
The company also terminated its prior at-the-market facility, which authorized up to $150.0 million in sales through multiple agents. The new agreement contains customary terms, including indemnification and conditions, and does not require funds to be placed in escrow.
Altimmune, Inc. announced an at-the-market equity program to sell, from time to time, shares of its common stock for up to $200.0 million under a prospectus supplement, with Leerink Partners LLC acting as sales agent. Sales will be made as “at the market offerings” under Rule 415(a)(4) on Nasdaq (symbol ALT).
The sales agent will receive a commission of up to 3.0% of the aggregate gross sales price, and will be deemed an underwriter. Altimmune states it intends to use net proceeds for working capital and general corporate purposes, which may include R&D, clinical and regulatory activities, potential acquisitions or investments, and possible repayment or repurchase of securities.
Shares outstanding were 95,598,665 as of September 30, 2025. The company notes there is no escrow arrangement and no obligation for the sales agent to sell a specific amount; offerings may be suspended or terminated in accordance with the agreement.
Altimmune reported Q3 2025 results with a net loss of $19.0 million as operating expenses declined versus last year. Research and development was $15.0 million, reflecting lower MASH trial spend, while general and administrative was $5.9 million.
Liquidity strengthened. Cash, cash equivalents, restricted cash and short‑term investments totaled $210.8 million as of September 30, 2025. The company raised $112.1 million year‑to‑date via at‑the‑market sales and drew a $15.0 million first tranche under a term loan. Subsequent to quarter‑end, Altimmune raised $33.8 million more through the ATM and amended its Hercules facility to $125.0 million, drawing a second $20.0 million tranche; the amended loan bears the greater of 9.70% or prime plus 2.45% with a 30‑month interest‑only period.
Pipeline updates noted 24‑week IMPACT Phase 2b MASH topline results, Fast Track designation for pemvidutide in AUD, and ongoing Phase 2 trials in AUD and ALD. Shares outstanding were 104,254,173 as of October 31, 2025.